Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Argx crawled time : 06:00 save search
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
Published: 2024-03-27 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.41%
H: 0.18%
C: -0.15%
disease
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.07%
H: 0.79%
C: -0.29%
japan vyvgart approval
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Published: 2024-02-29 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -3.06%
H: 0.31%
C: -1.44%
business year update financial results
argenx to Present at Upcoming Investor Conferences
Published: 2024-02-26 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.28%
H: 0.47%
C: -0.08%
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
Published: 2024-02-22 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.2%
H: 2.75%
C: 1.71%
report business year update financial results
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Published: 2024-02-20 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 3.75%
H: 0.26%
C: -2.84%
fda vyvgart license review application
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
Published: 2024-01-18 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.63%
H: 0.17%
C: -1.16%
vyvdura japan approval injection
argenx Highlights 2024 Strategic Priorities
Published: 2024-01-08 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.07%
H: 5.14%
C: 4.23%
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.74%
H: 1.36%
C: 0.9%
conference
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
Published: 2023-12-20 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -23.64%
H: 0.34%
C: -1.94%
topline results study
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
Published: 2023-11-28 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -8.82%
H: 0.4%
C: -1.49%
vyvgart topline results study
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
Published: 2023-11-01 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.8%
H: 4.96%
C: 4.53%
disease vyvgart sessions
argenx to Present at Upcoming Investor Conferences
Published: 2023-11-01 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.8%
H: 4.96%
C: 4.53%
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-10-31 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 2.8%
H: 0.48%
C: -1.59%
business update financial results
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
Published: 2023-09-21 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: -1.63%
authorized health vyvgart canada
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
Published: 2022-09-21 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: -3.44%
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
Published: 2022-06-24 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.57%
H: 0.65%
C: 0.52%
treatment europe chmp positive
argenx to Present at Upcoming Investor Conferences
Published: 2022-06-01 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -1.26%
H: 0.09%
C: -2.41%
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
Published: 2022-05-31 (Crawled : 06:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
granted grant
argenx to Present at Upcoming Investor Conferences
Published: 2021-09-03 (Crawled : 06:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.33%
H: 0.0%
C: 0.0%
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -0.9%
H: 2.01%
C: 1.34%
conference presentation
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.